New combo aims to supercharge immune attack on lymphoma
NCT ID NCT07138547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug eliglustat to CD30-targeted immunotherapy can make the treatment work better for people with CD30-positive lymphoma. About 40 adults who have already tried at least one other cancer treatment will receive either a CAR-T cell therapy or an antibody-drug conjugate, with or without eliglustat. The goal is to see if the combination is safe and improves response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
People's Liberation Army General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••